---
title: "Quoin Pharmaceuticals Approves Executive Cash Bonuses"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/243161622.md"
description: "Quoin Pharmaceuticals has approved 2024 cash bonuses for executives Dr. Michael Myers and Ms. Denise Carter, totaling $331,238 and $264,640, respectively. This decision aligns with the company's compensation programs established in December 2024. Despite a recent analyst rating of 'Buy' with a $70.00 price target, Quoin faces financial challenges, including no revenue and high reliance on external financing, leading to a bearish technical outlook and significant risks for investors."
datetime: "2025-06-04T20:40:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/243161622.md)
  - [en](https://longbridge.com/en/news/243161622.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/243161622.md)
generator: "portal-rs"
---

# Quoin Pharmaceuticals Approves Executive Cash Bonuses

### Confident Investing Starts Here:

-   Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-   Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Quoin Pharmaceuticals ( (QNRX) ) has issued an update.

On May 29, 2025, Quoin Pharmaceuticals Ltd.’s Compensation Committee approved 2024 annual cash bonuses for Dr. Michael Myers and Ms. Denise Carter, amounting to $331,238 and $264,640 respectively. These bonuses align with the CEO and COO Compensation Programs approved at the company’s annual meeting on December 5, 2024, reflecting the company’s commitment to rewarding its executive leadership.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

**Spark’s Take on QNRX Stock**

According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.

Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.

To see Spark’s full report on QNRX stock, click here. 

**More about Quoin Pharmaceuticals**

**Average Trading Volume:** 287,284

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $5.14M

See more data about QNRX stock on TipRanks’ Stock Analysis page.

## Trending Articles:

-   Paramount Stock (NASDAQ:PARA) Dips, Main Ad Agency Fired
-   Ford Financials May Look “A Bit Lumpy”; Ford Stock (NYSE:F) Notches Up Despite Unexpected Hiccups
-   “Intel Foundry Will Need to Earn (Intel’s) Business”: Intel Stock (NASDAQ:INTC) Slips as Intel Looks for Better Deal Than Intel

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

### Related Stocks

- [74907L409.US](https://longbridge.com/en/quote/74907L409.US.md)
- [QNRX.US](https://longbridge.com/en/quote/QNRX.US.md)

## Related News & Research

- [Cerebras (CBRS) vs. TSMC (TSM): Which Stock Has More Upside, According to Analysts?](https://longbridge.com/en/news/305260820.md)
- [Is AppLovin (APP) Undervalued Following Its Earnings Beat And Strong Guidance?](https://longbridge.com/en/news/305204186.md)
- [Nvidia’s Earnings Day Is ‘Earnings Day for Your 401(k).’ Here’s Why](https://longbridge.com/en/news/305204701.md)
- [How Investors May Respond To Alibaba (BABA) Dakar Olympics Cloud Deal](https://longbridge.com/en/news/305185166.md)
- [Baird, Morgan Stanley sour on Nvidia as CEO affair controversy deepens](https://longbridge.com/en/news/305197878.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**